

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted during the consultation that neuromyelitis optica spectrum disorder disproportionately impacts women as well as Black and Asian people, and that these are protected characteristics.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Issues related to differences in prevalence or incidence of a disease cannot typically be addressed in a technology appraisal. However, the committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes, the disproportionate impact of the condition on people of Black and Asian ethnicity has been added. The disproportionate impact on women was already included.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): Ross Dent

Date: 08/03/2023